Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Merck & Co. stops sale of cholesterol treatment

Drug maker Merck & Co. is suspending its sale of the cholesterol drug Tredaptive after initial results from a study showed that it wasn’t effective and could raise the risk of some serious side effects.

The Whitehouse Station, N.J., company said Friday it is telling doctors to quit prescribing the tablets, which are not approved in the United States, and is advising patients to stop taking the medication only after talking to a physician.

Continue reading below

The drug is sold in about 40 countries, including Europe.

Merck said last month initial results from a big, late-stage study showed that adding Tredaptive to traditional statin therapy failed to lower the risk of heart attack, stroke, and related problems. The drug maker said then that doctors should stop prescribing Tredaptive to new patients.

Results also showed that patients taking the cholesterol combination pill were more likely to suffer some serious, nonfatal adverse events.

Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week